Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

被引:39
|
作者
Mensah, Victorine A. [1 ]
Gueye, Aly [1 ]
Ndiaye, Magatte [1 ]
Edwards, Nick J. [2 ]
Wright, Danny [2 ]
Anagnostou, Nicholas A. [2 ]
Syll, Massamba [1 ]
Ndaw, Amy [1 ]
Abiola, Annie [1 ]
Bliss, Carly [2 ]
Gomis, Jules-Francois [1 ]
Petersen, Ines [3 ]
Ogwang, Caroline [4 ]
Dieye, Tandakha [1 ]
Viebig, Nicola K. [3 ]
Lawrie, Alison M. [2 ]
Roberts, Rachel [2 ]
Nicosia, Alfredo [5 ,6 ]
Faye, Babacar [1 ]
Gaye, Oumar [1 ]
Leroy, Odile [3 ]
Imoukhuede, Egeruan B. [2 ,3 ]
Ewer, Katie J. [2 ]
Bejon, Philip [4 ]
Hill, Adrian V. S. [2 ]
Cisse, Badara [1 ,7 ]
机构
[1] Fac Med Univ Cheikh Anta Diop, Dept Parasitol, Dakar, Senegal
[2] Univ Oxford, Jenner Inst, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England
[3] European Vaccine Initiat, Heidelberg, Germany
[4] Kenya Govt Med Res Ctr, Kilifi, Kenya
[5] ReiThera, Rome, Italy
[6] CEINGE, Via Gaetano Salvatore, Naples, Italy
[7] London Sch Hyg & Trop Med, London, England
来源
PLOS ONE | 2016年 / 11卷 / 12期
基金
英国医学研究理事会;
关键词
POLYMERASE-CHAIN-REACTION; MALARIA VACCINE; IMMUNIZATION; ANTIBODIES; REGIMEN; NAIVE; MSP1;
D O I
10.1371/journal.pone.0167951
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver viral vectors encoding the pre-erythrocytic antigen ME-TRAP (multiple epitope thrombospondin-related adhesion protein) have shown promising safety, immunogenicity and efficacy in sporozoite challenge studies. More recently, a study in Kenyan adults, similar to that reported here, showed substantial efficacy against P. falciparum infection. One hundred and twenty healthy male volunteers, living in a malaria endemic area of Senegal were randomised to receive either the Chimpanzee adenovirus (ChAd63) ME-TRAP as prime vaccination, followed eight weeks later by modified vaccinia Ankara (MVA) also encoding ME-TRAP as booster, or two doses of anti-rabies vaccine as a comparator. Prior to follow-up, antimalarials were administered to clear parasitaemia and then participants were monitored by PCR for malaria infection for eight weeks. The primary endpoint was time-to-infection with P. falciparum malaria, determined by two consecutive positive PCR results. Secondary endpoints included adverse event reporting, measures of cellular and humoral immunogenicity and a meta-analysis of combined vaccine efficacy with the parallel study in Kenyan adults. We show that this pre-erythrocytic malaria vaccine is safe and induces significant immunogenicity, with a peak T-cell response at seven days after boosting of 932 Spot Forming Cells (SFC)/10(6) Peripheral Blood Mononuclear Cells(PBMC) compared to 57 SFC/10(6) PBMCs in the control group. However, a vaccine efficacy was not observed: 12 of 57 ME-TRAP vaccinees became PCR positive during the intensive monitoring period as compared to 13 of the 58 controls (P = 0.80). This trial confirms that vaccine efficacy against malaria infection in adults may be rapidly assessed using this efficient and cost-effective clinical trial design. Further efficacy evaluation of this vectored candidate vaccine approach in other malaria transmission settings and age-de-escalation into the main target age groups for a malaria vaccine is in progress.
引用
收藏
页数:16
相关论文
共 27 条
  • [1] Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
    Ogwang, Caroline
    Afolabi, Muhammed
    Kimani, Domtila
    Jagne, Ya Jankey
    Sheehy, Susanne H.
    Bliss, Carly M.
    Duncan, Christopher J. A.
    Collins, Katharine A.
    Knight, Miguel A. Garcia
    Kimani, Eva
    Anagnostou, Nicholas A.
    Berrie, Eleanor
    Moyle, Sarah
    Gilbert, Sarah C.
    Spencer, Alexandra J.
    Soipei, Peninah
    Mueller, Jenny
    Okebe, Joseph
    Colloca, Stefano
    Cortese, Riccardo
    Viebig, Nicola K.
    Roberts, Rachel
    Gantlett, Katherine
    Lawrie, Alison M.
    Nicosia, Alfredo
    Imoukhuede, Egeruan B.
    Bejon, Philip
    Urban, Britta C.
    Flanagan, Katie L.
    Ewer, Katie J.
    Chilengi, Roma
    Hill, Adrian V. S.
    Bojang, Kalifa
    [J]. PLOS ONE, 2013, 8 (03):
  • [2] Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
    Victorine Mensah
    Danny Wright
    Katie Ewer
    Nick Edwards
    Magatte Ndiaye
    Phillip Bejon
    Nicola Viebig
    Babacar Faye
    Adrian Hill
    Badara Cisse
    [J]. Malaria Journal, 13 (Suppl 1)
  • [3] Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations
    Kimani, Domtila
    Jagne, Ya Jankey
    Cox, Momodou
    Kimani, Eva
    Bliss, Carly M.
    Gitau, Evelyn
    Ogwang, Caroline
    Afolabi, Muhannmed O.
    Bowyer, Georgina
    Collins, Katharine A.
    Edwards, Nick
    Hodgson, Susanne H.
    Duncan, Christopher J. A.
    Spencer, Alexandra J.
    Knight, Miguel G.
    Drammeh, Abdoulie
    Anagnostou, Nicholas A.
    Berrie, Eleanor
    Moyle, Sarah
    Gilbert, Sarah C.
    Soipei, Peninah
    Okebe, Joseph
    Colloca, Stefano
    Cortese, Riccardo
    Viebig, Nicola K.
    Roberts, Rachel
    Lawrie, Alison M.
    Nicosia, Alfredo
    Imoukhuede, Egeruan B.
    Bejon, Philip
    Chilengi, Roma
    Bojang, Kalifa
    Flanagan, Katie L.
    Hill, Adrian V. S.
    Urban, Britta C.
    Ewer, Katie J.
    [J]. MOLECULAR THERAPY, 2014, 22 (11) : 1992 - 2003
  • [4] Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
    Afolabi, Muhammed O.
    Tiono, Alfred B.
    Adetifa, Uche J.
    Yaro, Jean Baptiste
    Drammeh, Abdoulie
    Nebie, Issa
    Bliss, Carly
    Hodgson, Susanne H.
    Anagnostou, Nicholas A.
    Sanou, Guillaume S.
    Jagne, Ya Jankey
    Ouedraogo, Oumarou
    Tamara, Casimir
    Ouedraogo, Nicolas
    Ouedraogo, Mirielle
    Njie-Jobe, Jainaba
    Diarra, Amidou
    Duncan, Christopher J. A.
    Cortese, Riccardo
    Nicosia, Alfredo
    Roberts, Rachel
    Viebig, Nicola K.
    Leroy, Odile
    Lawrie, Alison M.
    Flanagan, Katie L.
    Kampman, Beate
    Bejon, Philip
    Imoukhuede, Egeruan B.
    Ewer, Katie J.
    Hill, Adrian V. S.
    Bojang, Kalifa
    Sirima, Sodiomon B.
    [J]. MOLECULAR THERAPY, 2016, 24 (08) : 1470 - 1477
  • [5] A phase I study to assess safety and immunogenicity of novel schedules for vaccination with candidate malaria vaccines ChAd63 ME-TRAP and MVA ME-TRAP
    Bliss, C. M.
    Ewer, K.
    Anagnostou, N.
    Havelock, T.
    Poulton, I.
    Lawrie, A.
    Choudhary, P.
    Hill, A.
    [J]. IMMUNOLOGY, 2011, 135 : 77 - 77
  • [7] Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
    Georgina Bowyer
    Muhammed O Afolabi
    Carly M Bliss
    Alfred B Tiono
    Abdoulie Drammeh
    Issa Nébié
    Ya Jankey Jagne
    Jean Baptiste Yaro
    Egeruan B Imoukhuede
    Katie L Flanagan
    Beate Kampman
    Nicola Viebig
    Sodiomon B Sirima
    Kalifa Bojang
    Adrian VS Hill
    Katie J Ewer
    [J]. Malaria Journal, 13 (Suppl 1)
  • [8] Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults
    Ogwang, Caroline
    Kimani, Domtila
    Edwards, Nick J.
    Roberts, Rachel
    Mwacharo, Jedidah
    Bowyer, Georgina
    Bliss, Carly
    Hodgson, Susanne H.
    Njuguna, Patricia
    Viebig, Nicola K.
    Nicosia, Alfredo
    Gitau, Evelyn
    Douglas, Sandy
    Illingworth, Joe
    Marsh, Kevin
    Lawrie, Alison
    Imoukhuede, Egeruan B.
    Ewer, Katie
    Urban, Britta C.
    Hill, Adrian V. S.
    Bejon, Philip
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (286)
  • [9] First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
    Tiono, Alfred B.
    Nebie, Issa
    Anagnostou, Nicholas
    Coulibaly, Aboubacar S.
    Bowyer, Georgina
    Lame, Erika
    Bougouma, Edith C.
    Ouedraogo, Alphonse
    Yaro, Jean Baptist B.
    Barry, Aissata
    Roberts, Rachel
    Rampling, Tommy
    Bliss, Carly
    Hodgson, Susanne
    Lawrie, Alison
    Ouedraogo, Amidou
    Imoukhuede, Egeruan Babatunde
    Ewer, Katie J.
    Viebig, Nicola K.
    Diarra, Amidou
    Leroy, Odile
    Bejon, Philip
    Hill, Adrian V. S.
    Sirima, Sodiomon B.
    [J]. PLOS ONE, 2018, 13 (12):
  • [10] IMMUNOGENICITY OF CHAD63/ MVA ME-TRAP MALARIA VECTORED VACCINE IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMIZED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES
    Roetynck, Sophie
    Mensah, Victorine
    Kanteh, Ebrima
    Bowyer, Georgina
    Ndaw, Amy
    Oko, Francis
    Bliss, Carly
    Cortese, Riccardo
    Nicosia, Alfredo
    Roberts, Rachel
    D'Alessio, Flavia
    Leroy, Odile
    Faye, Babacar
    Kampmann, Beate
    Cisse, Badara
    Bojang, Kalifa
    Gerry, Stephen
    Viebig, Nicola
    Lawrie, Alison
    Clarke, Ed
    Imoukhuede, Egeruan
    Ewer, Katie
    Hill, Adrian
    Afolabi, Muhammed
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 193 - 193